title: Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation.
abstract: We report the case of a 66-year-old man with primary diffuse large B-cell lymphoma of the prostate presenting with urinary retention and dyschezia as first manifestation. Although a colostomy was needed due to rectal obstruction, rituximab-combined chemotherapy resulted in complete remission. He underwent stoma closure safely and has remained in complete remission for over 3years. Primary prostatic lymphoma is extremely rare, presenting as 0.1% of newly diagnosed lymphomas, but rituximab-containing chemotherapy seems to be as effective as for nodal lymphoma.
authors.affiliation: Dept. of Hematology, Osaka City General Hospital.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Manabe
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Yumi
authors.initials: Y
authors.lastname: Yoshii
authors.forename: Satoru
authors.initials: S
authors.lastname: Mukai
authors.forename: Erina
authors.initials: E
authors.lastname: Sakamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kanashima
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nakao
authors.forename: Takuma
authors.initials: T
authors.lastname: Hayama
authors.forename: Hiroko
authors.initials: H
authors.lastname: Fukushima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Inoue
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yamane
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Teshima
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003248:Constipation / Q000209:etiology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011467:Prostate / Q000473:pathology*; D012004:Rectal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012074:Remission Induction; D000069283:Rituximab; D016055:Urinary Retention / Q000209:etiology*; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone